Forbes -- When AstraZeneca got U.S. clearance to sell the lung cancer-fighting pill Iressa in May 2003, it seemed to be a victory for patients and the company. Chief Executive Tom McKillop predicted the pill would become a “megabrand” with sales of more than $1 billion.
